Receptor antibodies as novel therapeutics for diabetes

scientific article

Receptor antibodies as novel therapeutics for diabetes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1126/SCITRANSLMED.3003447
P932PMC publication ID4374142
P698PubMed publication ID22174312

P50authorC. Ronald KahnQ16106681
Siegfried UssarQ43108049
P2093author name stringSara G Vienberg
P2860cites workTissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21Q24318639
FGF-21 as a novel metabolic regulatorQ24523933
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant StateQ24625976
New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditureQ24652521
Fibroblast growth factor 21: from pharmacology to physiologyQ24658126
Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase levelQ28237301
Cell-surface co-receptors: emerging roles in signaling and human diseaseQ30039645
Cellular bioenergetics as a target for obesity therapyQ33894407
Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese ratsQ33930333
Enterovirus RNA in blood is linked to the development of type 1 diabetesQ34448707
Extracellular interactome of the FGF receptor-ligand system: complexities and the relative simplicity of the wormQ37318049
TSH receptor autoantibodiesQ37426868
FGF21: a novel prospect for the treatment of metabolic diseases.Q37428992
Autoimmune disorders of the neuromuscular junctionQ37475932
Physiological inhibitors of Wnt signalingQ37845920
Fibroblast growth factors and their receptors in cancerQ37895306
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.Q39427414
Receptors, Antireceptor Antibodies and Mechanisms of Insulin ResistanceQ39783501
Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis.Q40508811
Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemiaQ43282888
Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemiaQ43986109
P433issue113
P407language of work or nameEnglishQ1860
P304page(s)113ps47
P577publication date2011-12-01
P1433published inScience Translational MedicineQ1573955
P1476titleReceptor antibodies as novel therapeutics for diabetes
P478volume3

Reverse relations

cites work (P2860)
Q40311070A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys
Q41161575Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice.
Q36058468An allosteric antibody to the leptin receptor reduces body weight and reverses the diabetic phenotype in the Lep(ob) /Lep(ob) mouse
Q36620162Epitope-specificity of recombinant antibodies reveals promiscuous peptide-binding properties
Q35095516Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity
Q41966485Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia.
Q38215993Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders
Q30234616The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes
Q38354696Theoretical and computational studies of peptides and receptors of the insulin family
Q54468633Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.
Q51350644XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity.

Search more.